The USA-based company applies drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss.
Otonomy's lead product, OTO-313, is a sustained-exposure formulation of gacycylidine, a potent and selective NMDA receptor antagonist, developed for the treatment of tinnitus.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze